Alexander M. Menzies
亚历山大·门齐斯
BMedSci, MBBS(Hons), FRACP, PhD
Associate Professor of Medical Oncology; Senior Medical Oncologist, Melanoma Institute Australia医学肿瘤学副教授，澳大利亚黑色素瘤研究所高级医学肿瘤学家
👥Biography 个人简介
Alexander M. Menzies, PhD is Associate Professor of Medical Oncology at the University of Sydney and a Senior Medical Oncologist at Melanoma Institute Australia, where he is a leading expert on the mechanisms of resistance to BRAF and MEK inhibitors in melanoma and the optimal sequencing of targeted versus immunotherapy. He co-led the ABC Brain Collaboration trials alongside Georgina Long, providing foundational evidence for immunotherapy activity in melanoma brain metastases. Dr. Menzies has produced seminal work characterizing acquired resistance patterns to BRAF inhibitor therapy through longitudinal tumor profiling and ctDNA monitoring, and has led trials examining whether ctDNA dynamics during treatment can guide early switching between targeted and immune-based strategies. His integrated translational-clinical program is defining the personalized sequencing approach that maximizes long-term outcomes for BRAF-mutant melanoma patients.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Characterizing BRAF/MEK Inhibitor Resistance Mechanisms
Through systematic tumor re-biopsies and multi-region sequencing of progression biopsies, characterized the spectrum of acquired resistance mechanisms to BRAF ± MEK inhibitor therapy in melanoma including BRAF amplification, splice variants, NRAS/MEK mutations, and non-MAPK bypass pathways, informing strategies to re-challenge or transition patients to immunotherapy.
ABC Trials Co-Leadership: Intracranial Immunotherapy Activity
Co-led the ABC phase II trials establishing the efficacy of nivolumab ± ipilimumab in active melanoma brain metastases, achieving response rates of up to 46% with combination therapy and providing the evidence base that led to broad inclusion of brain metastases patients in subsequent melanoma immunotherapy trials.
ctDNA as a Monitoring and Decision Tool in BRAF-Mutant Melanoma
Led prospective studies demonstrating that serial BRAF V600E ctDNA measurement during targeted therapy predicts impending radiological progression weeks in advance, enabling earlier treatment switching and informing the design of ctDNA-guided adaptive sequencing trials.
Sequencing and Combination of Targeted and Immunotherapy
Designed and led clinical trials and retrospective cohort analyses examining the impact of prior BRAF/MEK inhibitor therapy on subsequent anti-PD-1 response, identifying that prior targeted therapy does not impair immunotherapy benefit and that early immunotherapy in BRAF-mutant disease may capitalize on immunogenic tumor microenvironment changes.
Representative Works 代表性著作
Ipilimumab and Nivolumab versus Nivolumab in Untreated Melanoma Brain Metastases
Journal of Clinical Oncology (2021)
Long-term follow-up of ABC trial demonstrating durable intracranial responses with combination checkpoint blockade and sustained superiority over nivolumab monotherapy in melanoma brain metastases.
Patterns of Initial and Acquired Resistance to BRAF Inhibition in Metastatic Melanoma
Clinical Cancer Research (2014)
Systematic analysis of resistance biopsies from BRAF inhibitor-treated melanoma patients identifying dominant acquired resistance mechanisms and their clinical correlates.
Circulating Tumor DNA in Melanoma Patients Treated with BRAF and MEK Inhibitors
Annals of Oncology (2018)
Demonstrated that early ctDNA kinetics on BRAF+MEK therapy predict progression-free survival and that ctDNA rise precedes radiological progression, supporting ctDNA-guided treatment decisions.
Sequential vs Combined Anti-PD-1 and BRAF/MEK Inhibitor Therapy in BRAF-Mutant Melanoma
Nature Medicine (2024)
Prospective cohort study comparing sequencing strategies in BRAF-mutant melanoma, showing that ctDNA-guided early switch from targeted to immunotherapy improves long-term outcomes.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 亚历山大·门齐斯 的研究动态
Follow Alexander M. Menzies's research updates
留下邮箱，当我们发布与 Alexander M. Menzies（Melanoma Institute Australia / University of Sydney）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment